ERRATUM

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes

Søren S Lund¹, Lise Tarnow¹, Merete Frandsen¹, Ulla M Smidt¹, Oluf Pedersen^{1,2}, Hans-Henrik Parving^{2,3} and Allan A Vaag^{1,4}

¹Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark, ²Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark, ³Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark and ⁴Department of Endocrinology, University of Lund, S-20502 Malmö, Sweden

(Correspondence should be addressed to S S Lund; Email: sqrl@steno.dk)

The authors and the journal apologise for errors in the above paper which appeared in **158** (1) 35–46. In this paper, on page 38, under the results section, the first sentence of the second paragraph should read as follows:

‘At enrolment, 29 (30%) patients received lipid-lowering treatment as concomitant non-study medication (statin therapy, $n = 22$ (23%) – hereof 20 patients (21%) during the entire study period; fish oil, $n = 8$ (8%); acipimox, $n = 1$ (1%); none of the patients received fibrates).’

On page 40, in the results section under the heading ‘Subgroups of patients according to ongoing statin

treatment, pre-study antihyperglycaemic treatment regimens or known macrovascular disease’ the first sentence should read as follows:

‘Without fasting adjustment: statin treatment ($n = 18$): -0.39 mmol/l (-0.62 ; -0.17), $P = 0.001$; no statin treatment ($n = 55$): -0.16 mmol/l (-0.29 ; -0.02), $P = 0.021$; fasting adjusted: statin treatment ($n = 18$): -0.25 mmol/l (-0.38 ; -0.12), $P < 0.001$; no statin treatment ($n = 54$): -0.08 mmol/l (-0.15 ; -0.00), $P = 0.041$).’

On page 39 and on page 41, **Tables 2 and 3** should appear as follows:

Table 2 Comparison of effects of metformin and repaglinide on fasting and postprandial glycaemic variables during a standardized fatty meal test in non-obese patients with type 2 diabetes.

End point	End of treatment mean (s.d.) or median (range)		Change from first-period baseline mean (95% confidence interval)		Between-treatment effect mean (95% confidence interval)	
	Metformin	Repaglinide	ΔMetformin	ΔRepaglinide	Metformin versus repaglinide	P
Plasma glucose						
Fasting (mmol/l; <i>n</i> =89) ^a	11.24 (3.09)	11.30 (3.44)	−2.15 (−2.65; −1.64)	−2.07 (−2.59; −1.56)	−0.07 (−0.71; 0.57)	0.825
AUC (mmol/l; <i>n</i> =84) ^a	12.40 (3.74)	12.50 (4.34)	−3.69 (−4.30; −3.07)	−3.58 (−4.22; −2.95)	−0.10 (−0.86; 0.66)	0.790
AUC fasting adjusted (mmol/l; <i>n</i> =84) ^a	—	—	−3.77 (−4.08; −3.47)	−3.67 (−3.98; −3.36)	−0.11 (−0.49; 0.28)	0.585
Serum insulin						
Fasting (pmol/l ^b ; <i>n</i> =88) ^a	34 (6; 139)	39 (10; 114)	12 (2; 22) ^c	29 (17; 42) ^c	−13 (−20; −6) ^d	0.001
AUC (pmol/l ^b ; <i>n</i> =88) ^a	75 (29; 228)	106 (41; 330)	2 (−5; 10) ^c	41 (31; 52) ^c	−28 (−33; −22) ^d	<0.001
AUC fasting adjusted (pmol/l ^b ; <i>n</i> =88) ^a	—	—	6 (−0; 12) ^c	36 (28; 44) ^c	−22 (−27; −16) ^d	<0.001
Serum C-peptide						
Fasting (pmol/l ^b ; <i>n</i> =88) ^a	637 (253; 1340)	753 (253; 2015)	4 (−1; 10) ^c	20 (14; 26) ^c	−13 (−17; −8) ^d	<0.001
AUC (pmol/l ^b ; <i>n</i> =88) ^a	1184 (524; 2621)	1566 (587; 2626)	6 (2; 11) ^c	35 (29; 41) ^c	−21 (−25; −17) ^d	<0.001
AUC fasting adjusted (pmol/l ^b ; <i>n</i> =88) ^a	—	—	10 (6; 14) ^c	29 (25; 34) ^c	−15 (−19; −11) ^d	<0.001
HOMA-β (%) ^b (<i>n</i> =88) ^a	13.7 (2.3; 74.5)	14.2 (2.4; 95.4)	41 (27; 57) ^c	64 (47; 82) ^c	−14 (−24; −3) ^d	0.015
HOMA-IR ^b (<i>n</i> =88) ^a	2.2 (0.3; 7.5)	2.7 (0.6; 7.8)	−5 (−15; 6) ^c	9 (−2; 22) ^c	−13 (−22; −4) ^d	0.007

Total area under the curve (AUC) values are expressed per unit time of investigation, i.e. AUC for 360 min divided by 360 min. Fasting-adjusted results include the current level at time 0 as a covariate in the analysis. End of treatment levels represent raw absolute values, whereas change from first-period baseline and between-treatment effects represents estimates derived from the model. Homa-β, Homeostasis model assessment of β-cell function; HOMA-IR, Homeostasis model assessment of insulin resistance.

^aTotal number of patients with available data included in the default model (see Statistical section of Material and methods for details). Numbers of patients in each of the two treatment groups at end of treatment and as change from first-period baseline are not shown.

^bData are natural logarithmically transformed before analysis of change from first-period baseline and between-treatment effects.

^cPercentage change in the absolute levels at end of treatment versus at first-period baseline.

^dPercentage difference in the absolute change from first-period baseline between metformin (ΔMet) and repaglinide (ΔRep): ((ΔMet/ΔRep) − 1) × 100.

Table 3 Comparison of effects of metformin and repaglinide on fasting and postprandial lipid variables during a standardized fatty meal test in non-obese patients with type 2 diabetes.

Endpoint	End of treatment mean (S.D.) or median (range)		Change from first-period baseline mean (95% confidence interval)		Between-treatment effect mean (95% confidence interval)	
	Metformin	Repaglinide	ΔMetformin	ΔRepaglinide	Metformin versus repaglinide	P
Plasma total cholesterol						
Fasting (mmol/l; n=89) ^a	4.73 (0.86)	4.89 (0.85)	−0.23 (−0.34; −0.12)	−0.10 (−0.21; 0.01)	−0.13 (−0.25; −0.02)	0.026
AUC (mmol/l; n=85) ^a	4.68 (0.83)	4.85 (0.85)	−0.24 (−0.34; −0.14)	−0.08 (−0.18; 0.02)	−0.16 (−0.26; −0.05)	0.006
AUC fasting adjusted (mmol/l; n=85) ^a	—	—	−0.20 (−0.24; −0.17)	−0.15 (−0.18; −0.11)	−0.06 (−0.10; −0.01)	0.010
Plasma LDL cholesterol						
Fasting (mmol/l; n=87) ^a	2.81 (0.68)	3.04 (0.76)	−0.25 (−0.34; −0.15)	−0.06 (−0.16; 0.04)	−0.19 (−0.29; −0.08)	0.001
AUC (mmol/l; n=69) ^a	2.56 (0.70)	2.78 (0.71)	−0.23 (−0.32; −0.13)	−0.06 (−0.15; 0.04)	−0.17 (−0.26; −0.08)	0.001
AUC fasting adjusted (mmol/l; n=69) ^a	—	—	−0.18 (−0.21; −0.15)	−0.13 (−0.16; −0.10)	−0.05 (−0.10; −0.01)	0.027
Plasma non-HDL cholesterol						
Fasting (mmol/l; n=89) ^a	3.55 (0.88)	3.73 (0.89)	−0.29 (−0.40; −0.18)	−0.14 (−0.25; −0.03)	−0.15 (−0.27; −0.04)	0.011
AUC (mmol/l; n=84) ^a	3.53 (0.85)	3.74 (0.88)	−0.32 (−0.42; −0.22)	−0.14 (−0.24; −0.04)	−0.18 (−0.29; −0.07)	0.001
AUC fasting adjusted (mmol/l; n=84) ^a	—	—	−0.27 (−0.30; −0.24)	−0.21 (−0.25; −0.18)	−0.06 (−0.10; −0.02)	0.005
Plasma HDL cholesterol						
Fasting (mmol/l; n=89) ^a	1.18 (0.28)	1.16 (0.33)	0.06 (0.03; 0.10)	0.04 (0.01; 0.08)	0.02 (−0.02; 0.06)	0.276
AUC (mmol/l; n=84) ^a	1.13 (0.27)	1.11 (0.31)	0.07 (0.03; 0.11)	0.06 (0.02; 0.10)	0.01 (−0.02; 0.05)	0.474
AUC fasting adjusted (mmol/l; n=84) ^a	—	—	0.06 (0.05; 0.07)	0.06 (0.05; 0.07)	0.00 (−0.01; 0.01)	0.925
Plasma triglycerides						
Fasting (mmol/l ^b ; n=89) ^a	1.24 (0.40; 8.68)	1.46 (0.40; 7.68)	−7 (−14; 1) ^c	−9 (−17; −1) ^c	3 (−5; 12) ^d	0.478
AUC (mmol/l ^b ; n=85) ^a	2.03 (0.69; 8.28)	1.98 (0.66; 8.85)	−6 (−12; 1) ^c	−10 (−17; −3) ^c	5 (−2; 12) ^d	0.164
AUC fasting adjusted (mmol/l ^b ; n=85) ^a	—	—	−9 (−12; −5) ^c	−8 (−11; −5) ^c	−1 (−5; 4) ^d	0.751
Serum-free fatty acids						
Fasting (μmol/l; n=88) ^a	537 (199)	519 (231)	4 (−34; 42)	−14 (−52; 25)	18 (−26; 62)	0.418
AUC (μmol/l; n=84) ^a	366 (116)	344 (122)	−50 (−69; −32)	−66 (−85; −46)	16 (−5; 36)	0.143
AUC fasting adjusted (μmol/l; n=84) ^a	—	—	−52 (−69; −36)	−63 (−80; −46)	11 (−8; 30)	0.259

Total area under the curve AUC values are expressed per unit time of investigation, i.e. AUC for 360 min divided by 360 min. Fasting-adjusted results include the current level at time 0 as a covariate in the analysis. End of treatment levels represent raw absolute values, whereas change from first-period baseline and between-treatment effects represents estimates derived from the model. LDL, low-density lipoprotein; HDL, high-density lipoprotein; Non-HDL, non-high-density lipoprotein.

^aTotal number of patients with available data included in the default model (see statistical section of Materials and methods for details). Numbers of patients in each of the two treatment groups at end of treatment and as change from first-period baseline are not shown.

^bData are natural logarithmically transformed before analysis of change from first-period baseline and between-treatment effects.

^cPercentage change in the absolute levels at end of treatment versus the absolute levels at first-period baseline.

^dPercentage difference in the absolute change from first-period baseline between metformin (ΔMet) and repaglinide (ΔRep): ((ΔMet/ΔRep) − 1) × 100.